All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
S14 Ep50: Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS
OncLive® On Air
9 minutes
5 days ago
S14 Ep50: Distinct Risk Factors for Bladder Cancer in Women Necessitate Diligent Early Detection Strategies: With Martha K. Terris, MD, FACS
Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.
OncLive® On Air
Dr Erba discusses the FDA approval of ziftomenib for the treatment of adult patients with relapsed/refractory AML with a susceptible NPM1 mutation.
